Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

Abstract Background A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG...

Full description

Bibliographic Details
Main Authors: Ji-Yeon Kim, Seri Park, Seock-Ah Im, Sung-Bae Kim, Joohyuk Sohn, Keun Seok Lee, Yee Soo Chae, Ki Hyeong Lee, Jee Hyun Kim, Young-Hyuck Im, Tae-Yong Kim, Kyung-Hun Lee, Jin-Hee Ahn, Gun Min Kim, In Hae Park, Soo Jung Lee, Hye Sook Han, Se Hyun Kim, Kyung Hae Jung, Yeon Hee Park, Korean Cancer Study Group
Format: Article
Language:English
Published: Wiley 2019-05-01
Series:Cancer Communications
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40880-019-0375-7
id doaj-6129f5be80104cb281fcc3c9e6701361
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Ji-Yeon Kim
Seri Park
Seock-Ah Im
Sung-Bae Kim
Joohyuk Sohn
Keun Seok Lee
Yee Soo Chae
Ki Hyeong Lee
Jee Hyun Kim
Young-Hyuck Im
Tae-Yong Kim
Kyung-Hun Lee
Jin-Hee Ahn
Gun Min Kim
In Hae Park
Soo Jung Lee
Hye Sook Han
Se Hyun Kim
Kyung Hae Jung
Yeon Hee Park
Korean Cancer Study Group
spellingShingle Ji-Yeon Kim
Seri Park
Seock-Ah Im
Sung-Bae Kim
Joohyuk Sohn
Keun Seok Lee
Yee Soo Chae
Ki Hyeong Lee
Jee Hyun Kim
Young-Hyuck Im
Tae-Yong Kim
Kyung-Hun Lee
Jin-Hee Ahn
Gun Min Kim
In Hae Park
Soo Jung Lee
Hye Sook Han
Se Hyun Kim
Kyung Hae Jung
Yeon Hee Park
Korean Cancer Study Group
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Cancer Communications
Metastatic breast cancer
Eribulin
Paclitaxel
Neuropathy
Quality of life
Functional assessment of cancer therapy-taxane questionnaires
author_facet Ji-Yeon Kim
Seri Park
Seock-Ah Im
Sung-Bae Kim
Joohyuk Sohn
Keun Seok Lee
Yee Soo Chae
Ki Hyeong Lee
Jee Hyun Kim
Young-Hyuck Im
Tae-Yong Kim
Kyung-Hun Lee
Jin-Hee Ahn
Gun Min Kim
In Hae Park
Soo Jung Lee
Hye Sook Han
Se Hyun Kim
Kyung Hae Jung
Yeon Hee Park
Korean Cancer Study Group
author_sort Ji-Yeon Kim
title Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
title_short Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
title_full Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
title_fullStr Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
title_full_unstemmed Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
title_sort quality of life outcomes including neuropathy-associated scale from a phase ii, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for her2-negative metastatic breast cancer: korean cancer study group trial (kcsg br13-11)
publisher Wiley
series Cancer Communications
issn 2523-3548
publishDate 2019-05-01
description Abstract Background A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional assessment of cancer therapy-taxane (FACT-Taxane) questionnaires from patients in this clinical trial to determine their quality of life (QoL). Methods QoL was assessed using the Korean version of the FACT-Taxane questionnaires. After baseline assessment, QoL was assessed every 2 cycles for 12 cycles and every 3 cycles thereafter. The linear mixed model was used to evaluate the difference in QoL between the EG and PG arms. Results Of the 118 enrolled patients, 117 responded to the FACT-Taxane questionnaires at baseline, 1 in the PG arm did not. Baseline QoL scores were not different between the EG and PG arms. During treatment, taxane subscale scores were significantly higher in the PG arm than in the EG arm after 2–13 cycles of chemotherapy (all P < 0.05), except for the 11th cycle. Neuropathy-specific analysis showed that patients in the PG arm had earlier and more severe neuropathic symptoms than those in the EG arm (P < 0.001). Conclusions In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regimen. Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC.
topic Metastatic breast cancer
Eribulin
Paclitaxel
Neuropathy
Quality of life
Functional assessment of cancer therapy-taxane questionnaires
url http://link.springer.com/article/10.1186/s40880-019-0375-7
work_keys_str_mv AT jiyeonkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT seripark qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT seockahim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT sungbaekim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT joohyuksohn qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT keunseoklee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT yeesoochae qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT kihyeonglee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT jeehyunkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT younghyuckim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT taeyongkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT kyunghunlee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT jinheeahn qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT gunminkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT inhaepark qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT soojunglee qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT hyesookhan qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT sehyunkim qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT kyunghaejung qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT yeonheepark qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
AT koreancancerstudygroup qualityoflifeoutcomesincludingneuropathyassociatedscalefromaphaseiimulticenterrandomizedtrialoferibulinplusgemcitabineversuspaclitaxelplusgemcitabineasfirstlinechemotherapyforher2negativemetastaticbreastcancerkoreancancerstudygrouptrialkcsgbr1311
_version_ 1724863179904778240
spelling doaj-6129f5be80104cb281fcc3c9e67013612020-11-25T02:22:08ZengWileyCancer Communications2523-35482019-05-013911810.1186/s40880-019-0375-7Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)Ji-Yeon Kim0Seri Park1Seock-Ah Im2Sung-Bae Kim3Joohyuk Sohn4Keun Seok Lee5Yee Soo Chae6Ki Hyeong Lee7Jee Hyun Kim8Young-Hyuck Im9Tae-Yong Kim10Kyung-Hun Lee11Jin-Hee Ahn12Gun Min Kim13In Hae Park14Soo Jung Lee15Hye Sook Han16Se Hyun Kim17Kyung Hae Jung18Yeon Hee Park19Korean Cancer Study GroupDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan UniversityDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, College of Medicine, Seoul National UniversityDepartment of Oncology, Asan Medical Center, University of Ulsan College of MedicineDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of MedicineCenter for Breast Cancer, National Cancer CenterDepartment of Internal Medicine, Kyungpook National University HospitalDeparment of Internal Medicine, Chungbuk National University HospitalDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, College of Medicine, Seoul National UniversityDepartment of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, College of Medicine, Seoul National UniversityDepartment of Oncology, Asan Medical Center, University of Ulsan College of MedicineDivision of Medical Oncology, Department of Internal Medicine, Yonsei University College of MedicineCenter for Breast Cancer, National Cancer CenterDepartment of Internal Medicine, Kyungpook National University HospitalDeparment of Internal Medicine, Chungbuk National University HospitalDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of MedicineDepartment of Oncology, Asan Medical Center, University of Ulsan College of MedicineDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineAbstract Background A phase II clinical trial of the comparison between eribulin plus gemcitabine (EG) and paclitaxel plus gemcitabine (PG) as first-line chemotherapy for patients with metastatic breast cancer (MBC) found that the EG regimen was less neurotoxic, but was similar in efficacy to the PG regimen. In the present study, we analyzed functional assessment of cancer therapy-taxane (FACT-Taxane) questionnaires from patients in this clinical trial to determine their quality of life (QoL). Methods QoL was assessed using the Korean version of the FACT-Taxane questionnaires. After baseline assessment, QoL was assessed every 2 cycles for 12 cycles and every 3 cycles thereafter. The linear mixed model was used to evaluate the difference in QoL between the EG and PG arms. Results Of the 118 enrolled patients, 117 responded to the FACT-Taxane questionnaires at baseline, 1 in the PG arm did not. Baseline QoL scores were not different between the EG and PG arms. During treatment, taxane subscale scores were significantly higher in the PG arm than in the EG arm after 2–13 cycles of chemotherapy (all P < 0.05), except for the 11th cycle. Neuropathy-specific analysis showed that patients in the PG arm had earlier and more severe neuropathic symptoms than those in the EG arm (P < 0.001). Conclusions In our QoL analysis, the EG regimen delayed and decreased neuropathy as compared with the PG regimen. Therefore, eribulin would be a reasonable substitute for paclitaxel as first-line chemotherapy for MBC.http://link.springer.com/article/10.1186/s40880-019-0375-7Metastatic breast cancerEribulinPaclitaxelNeuropathyQuality of lifeFunctional assessment of cancer therapy-taxane questionnaires